{
    "nct_id": "NCT05737706",
    "official_title": "A Phase 1/2 Multiple Expansion Cohort Trial of MRTX1133 in Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation",
    "inclusion_criteria": "* Histologically confirmed diagnosis of a solid tumor malignancy harboring KRAS G12D mutation in tumor tissue or ctDNA.\n* Unresectable or metastatic disease.\n* Patients must have received standard therapies appropriate for their tumor type and stage; first-line treatment for PDAC for certain cohorts.\n* Presence of tumor lesions to be evaluated per RECIST v1.1:\n\n  1. in the Phase 1 dose escalation cohorts, patients must have measurable or evaluable disease.\n  2. in the Phase 1b and Phase 2 cohorts, patients must have measurable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Adequate organ function.\n* Age â‰¥ 18 years\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active brain metastases or carcinomatous meningitis.\n* Prior treatment with a KRAS G12D inhibitor (Phase 1b & Phase 2 only).\n* History of significant hemoptysis or hemorrhage within 4 weeks of the first dose of study treatment.\n* History of intestinal disease, inflammatory bowel disease, major gastric surgery, or other gastrointestinal conditions likely to alter absorption of study treatment or result in inability to swallow oral medications.\n* History of malignant small bowel obstruction.\n* Cardiac abnormalities.",
    "miscellaneous_criteria": ""
}